Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts.

Nature communications·2026
Same author

Aβ- and tau-associated neuroinflammatory signatures in Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Eligibility for anti-amyloid treatment in a multiethnic community-based study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Tau extent outperforms tau load as a predictor of neurodegeneration in Alzheimer's disease.

Molecular neurodegeneration·2026
Same author

Hemispheric lateralization of Tau associations with visual and verbal memory in Alzheimer's disease.

European journal of nuclear medicine and molecular imaging·2026
Same author

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.

Lancet (London, England)·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Marina P Gonçalves1, Tevy Chan1, Arthur C Macedo1

  • 1Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

粉样性粉症的APOEɛ4载体显示出血p-tau217水平的更快进展. 这种阿尔茨海默病生物标志物变化没有被观察到p-tau181或p-tau231,突出显示了疾病进展中的特定相互作用.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 遗传学 是一个遗传学.
  • 生物标志物研究 生物标志物研究

背景情况:

  • 无脂蛋白E ɛ4基因 (APOEɛ4) 是阿尔茨海默病 (AD) 的关键遗传风险因素.
  • APOEɛ4载体对粉样β (Aβ) 疗法的反应减弱,疾病进展发生改变.
  • 血生物标志物为监测AD状态和治疗反应提供了一种不那么侵入性的方法.

研究的目的:

  • 调查APOEɛ4载体和非载体之间酸化 (p-tau) 血水平的差异.
  • 检查这些差异与大脑氨基粉症的存在或不存在有关.
  • 评估血p-tau生物标志物的纵向进展,在APOEɛ4状态和粉样蛋白阳性的背景下.

主要方法:

  • 利用了TRIAD (转化生物标志物在衰老和痴呆症中的转化生物标志物) 队列的数据.
  • 使用PET成像评估大脑粉样β和陶.
  • 使用商业和内部测定量的量化血p-tau181,p-tau217和p-tau231.
  • 根据APOEɛ4载体状态和粉样蛋白阳性 (PET或CSF Aβ42/40比率) 分类参与者.
  • 采用横截面和纵向统计分析来比较生物标志物水平和进展率.

主要成果:

  • 在APOEɛ4载体和非载体之间没有发现血p-tau181,p-tau231或p-tau217的显著基线差异,无论粉样蛋白状况如何.
  • 纵向分析显示,基于APOEɛ4状态的p-tau181或p-tau231进展率没有差异.
  • 在粉胺阳性参与者中观察到血p-tau217的加速增加,但这种进展在A+个体中没有受到APOEɛ4载体状态的显著调节.
  • 在p-tau217进展中,APOEɛ4载体和Aβ状态之间的附加相互作用被注意到.

结论:

  • 血p-tau217的进展在粉样性粉症患者中加速,由APOEɛ4载体的附加效应.
  • APOEɛ4状态没有影响血p-tau181或p-tau231在amyloidosis存在时的进展率.
  • 需要进一步的研究,以充分阐明APOEɛ4,粉样状况和AD生物标志物的进展之间的复杂相互作用.